Skip to content
etf.net

Launched · SEC filings

AdvisorShares Psychedelics ETF

PSILNYSE ArcaAdvisorSharesF

$19.08−1.92 (−9.14%)

At close: Nov 2, 2026, 4:00 PM ET

F19/ 100

Rank 9 of 9 in Pharma & Therapeutics

F19/100Rank 9 of 9inPharma & Therapeutics
Intraday session: down, 78 prints from 21.00 to 19.08. Range 18.86 to 20.73. Use the arrow keys to read each point.19.5020.0020.5010 AM12 PM2 PM4 PM
Expense ratio
1.00%*
Fund size
$45M
1Y total return
+15.5%
Yield · Last 12 months
8.02%
Holdings
26
Avg volume · 30D
37.7K sh
52W range
low $15.63high $27.02
Launched
Filings
SEC EDGAR

*After a fee waiver that ends Nov 1, 2027. Without it: 1.28%.

The ETF.net PSIL Grade

Based on 5 of 6 pillars

F

Score 19 out of 100

Category
Pharma & Therapeutics⁠
Rank
9 of 9
Six-pillar profile for PSIL. Scores out of 100: Cost 6, Risk 20, Mission not scored, Tradability 21, Holdings 55, Durability 25. Strongest: Holdings (55). Weakest: Cost (6). Based on 5 of 6 pillars.

Score 19 of 100 falls in the F band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    F6 out of 100
    Rank 9 of 9

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    F20 out of 100
    Rank 9 of 9

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    F21 out of 100
    Rank 8 of 9

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    B55 out of 100
    Rank 5 of 9

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    D25 out of 100
    Rank 8 of 9

Our read on PSIL

ETF.net Research

In short

FThe ticker is the thesis. PSIL is a compact, global, actively run basket of health care companies working on psychedelic medicine, with a stated goal of long-term capital appreciation in a corner of the market almost no other ETF touches.

Stated mandate

The Fund seeks long-term capital appreciation.

Why people hold it

  • One ticker, the whole theme: a global basket of roughly two dozen health care names tied to psychedelic medicine, instead of hand-picking single clinical-stage stocks.advisorshares.com
  • Concentrated on purpose. At around 25 positions, the theme stays front and center rather than getting diluted inside a broad mega-cap pharma index.
  • Trading since 2021, so there is multi-year live operating history behind the strategy, not a simulated one.

Worth knowing

  • Expensive by pharma-ETF standards: 1.84% a year, against 0.36% at PPH and 0.35% at XPH. A niche, actively managed mandate carries a niche price tag.
  • Small asset base and light trading volume. Spreads can be wide, so limit orders are the standard way to deal with a fund this thinly traded.
  • Within its pharma and therapeutics peer group it sits in the bottom quartile, held back mainly by cost and tradability rather than the theme itself.

PSIL Holdings

Holdings pillarB55 out of 100Rank 5 of 9 in Pharma & Therapeutics
Asset class
Stocks
Holdings
26
Top-10 weight
68%
Largest holding
DFTX12.0%

Sectors

  • Health Care100.0%

Geography

  • United States67.91%
  • Canada14.52%
  • United Kingdom12.32%
  • Ireland4.36%
  • Australia0.89%
The fund’s holdings, weight-ordered — page 1 of 2.
#TickerCompanyWeight %SharesMarket valueHeld by ETFs
1DFTXDefinium Therapeutics Inc12.01%150,124$5.45M73
2CMPSCompass Pathways PLC11.68%458,395$5.3M19
3HELPHelus Pharma Inc8.40%360,147$3.82M5
4LLYEli Lilly & Co6.12%1,960$2.78M593
5ABBVAbbVie Inc5.50%8,471$2.5M523
6NBIXNeurocrine Biosciences Inc5.13%15,954$2.33M250
7RLMDRelmada Therapeutics Inc5.07%643,176$2.3M42
8JNJJohnson & Johnson4.84%8,042$2.2M524
9STIMNeuronetics Inc4.70%948,644$2.13M6
10DRUGBright Minds Biosciences Inc4.63%38,217$2.1M28
11SPTXSeaport Therapeutics Inc4.50%104,334$2.04M35
12GHRSGh Research PLC4.23%92,038$1.92M7
13ANROAlto Neuroscience Inc3.77%75,847$1.71M59
14SUPNSupernus Pharmaceuticals Inc3.38%36,583$1.53M117
15NRXPNrx Pharmaceuticals Inc3.35%670,811$1.52M4

Showing 1–15 of 26 holdings

PSIL Performance

Launched Sep 15, 2021

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.
PSIL$11,554
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. PSIL $11,554. SPY $11,199. Use the arrow keys to read each point.$10,000$12,000$14,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for PSIL. Periods over one year show the average yearly return.
PeriodPSIL
Year to date+22.3%
1 month−6.7%
3 months−10.6%
1 year+15.5%
3 yearsper year+16.9%
5 yearsper year−24.0%
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for PSIL
YearReturn barPSIL
2026 YTD+22.3%
2025+74.1%
2024−19.5%

PSIL in the news

PSIL Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
8.02%Last 12 months
Payout per share
$1.68Last 12 months
Last payment
$1.68 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Quarterly

Distribution history

2024–2026

One bar per payment. 6 payments from 2024 to 2026 YTD. Sep 23, 2024 $0.11; Dec 23, 2024 $0.05; Mar 21, 2025 $0.16; Jun 23, 2025 $0.01; Sep 22, 2025 $0.02; Dec 22, 2025 $1.68. Use the arrow keys to read each point.202420252026YTD
Ex-datePay dateAmount per share
Dec 22, 2025Dec 29, 2025$1.68
Sep 22, 2025Sep 29, 2025$0.02
Jun 23, 2025Jun 27, 2025$0.01
Mar 21, 2025Mar 28, 2025$0.16
Dec 23, 2024Dec 30, 2024$0.05
Sep 23, 2024Sep 30, 2024$0.11
Sep 25, 2023Sep 29, 2023No data
Sep 26, 2022Sep 30, 2022No data

$10,000 in PSIL 5 years ago paid $202 in dividends.

PSIL Risk

Risk pillarF20 out of 100Rank 9 of 9 in Pharma & Therapeutics
How much the fund’s monthly returns vary, scaled to a year.
46.8%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.44
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−92.8%
Trough Oct 2024
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.56
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

PSIL Cost

Compare PSIL and PBPH

Overpaying vs PBPH, cheapest in Pharma & Therapeutics

$15,962

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • PSIL 1.00%

    $18,688

  • PBPH 0.13% Cheapest

    $2,726

$10,000
30 years

Cost over time

  • PSIL 1.00%
  • PBPH 0.13%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$5K$10K$15K$20K051015202530PSIL $18,688PBPH $2,726

Year by year

YearPSILPBPHOverpaying
10$1,763$238$1,525
20$6,625$930$5,695
30$18,688$2,726$15,962
How the 1.00% is worked out

Full fee 1.28%− waiver 0.28%= you pay 1.00%

The waiver ends Nov 1, 2027. After that the fee is 1.28% unless AdvisorShares renews it. Source: prospectus, Oct 2026.

Other funds in Pharma & Therapeutics

See others